Related Experiment Video

Updated: Jun 16, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

Tri K Nguyen1, Nicholas Jordan, Jonathan Friedberg

  • 1Department of Medicine, Institute of Molecular Medicine and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.

Leukemia Research
|February 2, 2010
PubMed

Insights

Combining sorafenib with MEK1/2 inhibitors enhances apoptosis in diffuse large B-cell lymphoma (DLBCL) cells. This combination therapy targets Mcl-1, offering a new strategy for lymphoma treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • Sorafenib, a multi-kinase inhibitor, shows activity but requires optimization for enhanced efficacy.
  • Understanding drug interactions is crucial for developing effective DLBCL therapies.

Purpose of the Study:

  • To investigate the synergistic effects of sorafenib and MEK1/2 inhibitors in DLBCL cells.
  • To elucidate the molecular mechanisms underlying the combined drug action.
  • To provide a rationale for clinical application of this combination therapy.

Main Methods:

  • Treatment of DLBCL cell lines with sorafenib and MEK1/2 inhibitors (PD184352).
  • Assessment of apoptosis induction and ERK1/2 signaling pathway activation.
  • Gene silencing using MEK1 shRNA and ectopic Mcl-1 expression.
  • Western blot analysis for Mcl-1 and Bim(EL) protein levels.

Main Results:

  • Sorafenib induced apoptosis in DLBCL cells but did not consistently inactivate ERK1/2, sometimes causing activation.
  • MEK1/2 inhibition abrogated sorafenib-induced ERK1/2 activation and synergistically enhanced apoptosis.
  • MEK1 knockdown and combined sorafenib/PD184352 treatment accelerated Mcl-1 downregulation.
  • Overexpression of Mcl-1 reduced apoptosis induced by the combination therapy.

Conclusions:

  • MEK1/2 inhibitors can potentiate the anti-lymphoma activity of sorafenib in DLBCL.
  • The synergistic effect involves Mcl-1 downregulation and is independent of Bim(EL) upregulation.
  • This study provides a strong preclinical basis for combining sorafenib with MEK1/2 inhibitors in DLBCL treatment.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...